Company With Portfolio of AI Solutions Assisting Patients’ Neurological Conditions

AI For Imaging

Image-recognition tasks, powered by artificial intelligence (AI) algorithms, can attain serious results when it comes to recognizing complex patterns in imaging data in radiology.

According to Bibb Allen, MD, FACR, CMO of the ACR’s Data Science Institute (DSI), “We believe that AI is poised to significantly increase the value radiology professionals are able to provide their patients. Adding information acquired from AI algorithms to our reporting and workflow can significantly improve patient care. While AI for imaging will not come all at once, early adopters of AI in their practices will be ready to be future leaders in health care.”

With that said, there are plenty of startups and bigger companies revolutionizing patient care through imaging AI.

Look at icometrix, for instance — Founded in 2011 by Wim Van Hecke and Dirk Loeckx, the Leuven, Belgium-based company strives for data-driven insights and personalized patient care, supported by — yes, you guessed it, AI.

Icometrix’s expertise lies in its clinical icobrain portfolio, a cloud-based AI solution to quantify disease-specific brain structures on MR and CT.

• MR for epilepsy, multiple sclerosis, brain tumours, dementia, traumatic brain injury, and brain development

• CT for traumatic brain injury, strokes and dementia

• Advanced MRI for brain diffusion, perfusion, function, myelination, and metabolites

“We have a great team that works so hard every day to help people with neurological disorders such as multiple sclerosis, dementia, epilepsy, brain trauma, or other disorders. We have a great passion that resulted in our CE and FDA-cleared icobrain-tools that are being used worldwide.

Together, we’re reshaping the future of healthcare.”

 — Wim Van Hecke, CEO icometrix

Additionally, icompanion, a digital platform, and the mobile app, helps people with MS and their care team to monitor clinical symptoms and treatments efficiently and objectively.

Icolung, on the other hand, addresses the COVID-19 pandemic by measuring lung involvement on chest CT.

Icometrix’s AI platform is internationally active and integrated into more than 100 clinical practices and supports pharmaceutical companies in phase I-III and Real-World Evidence (RWE) studies.

Having raised a total of $20.2 million in funding over two rounds, icometrix’s AI solution that assists healthcare with various challenges in neurological disorders has all the financial resources it needs.

Icometrix’s Co-Founder and CEO, Wim Van Hecke, is also a Visiting Professor at the Vrije Universiteit Brussel. He has a Ph.D. in Magnetic Resonance Imaging from the University of Antwerp.

Dirk Loeckx, icometrix’s second Co-Founder, is a healthtech entrepreneur, who from 2011 to 2020 acted in several roles for the startup from CEO, COO to Board Member. Prior to icometrix, Loeckx was a Ph.D. and Senior Researcher at KU Leuven.

Loeckx obtained a Ph.D. in Biomedical Engineering from KU Leuven and an MBA from the Vlerick Business School.

AI is transforming healthcare through disruptive innovation. icometrix, as well as others, are on the cutting edge of this innovation that is set to get even bigger.